TRICARE Pharmacy Program RFI

The Defense Health Agency (DHA) is in the acquisition planning phase for the next generation TRICARE Pharmacy Program (TPharm) contract. This Request For Information (RFI) is the method for initiating market research efforts as the Government begins to build requirements and documentation related to this program.

Disclaimer: This announcement does not constitute a commitment, implied or otherwise that a solicitation or contract will be issued. Issuance of the RFI is for planning purposes only and does not commit the Government to any contractual agreements or arrangements. The Government is not soliciting proposals with this request. Please note that the collection of the requested information does not obligate the Government to incorporate solicited comments or procure any services.

Responses to this announcement will not be returned. The Government is not liable to pay any costs associated with companies responding to this announcement. Issuance of the RFI is intended to provide interested parties with information on the anticipated procurement and provide an opportunity for industry feedback into the preliminary programmatic design. All information received resulting from this RFI will be used by the DHA as market research.

However, responses may be releasable to the public under the Freedom of Information Act (FOIA) unless appropriately marked. The DHA, at its discretion, may request respondents to elaborate on information in their written response in writing or through other means. Respondents will not be notified of any results derived from a review of the information provided. Any responses from the Government are subject to change, as the requirements themselves remain in draft form.

Interested parties will have opportunity to seek clarification from the Government for any remaining questions, particularly those pertaining to evaluation criteria, incentives, or contract requirements, at the final RFP stage. All responses must be provided via email to dha.buckley.ad-spt-cae.mbx.tpharm6@health.mil by January 30, 2026 12:00 pm MST.